Pharmacogenomic challenges in cardiovascular diseases: Examples of drugs and considerations for future integration in clinical practice

Current Pharmaceutical Biotechnology

Volumn 18, Issue 3, 2017, Pages 231-241

  Chatelin, Jérôme ^a,b   Stathopoulou, Maria G ^a   Arguinano, Alex Ander A ^a   Xie, Ting ^a   Visvikis Siest, Sophie ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Cardiovascular diseases; Drugs; Environment interactions; Gene interactions; Genome; Omics; Personalized medicine; Pharmacogenomics

Indexed keywords

ANTIINFLAMMATORY AGENT; CLOPIDOGREL; CYTOCHROME P450; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TICAGRELOR; TRIACYLGLYCEROL; CARDIOVASCULAR AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; CYP3A5 GENE; DNA SEQUENCE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERANCE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HMGCR GENE; HORMONAL THERAPY; HUMAN; HUMAN GENOME; ISCHEMIC HEART DISEASE; MUSCULOSKELETAL DISEASE; MYOPATHY; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VKORC1 GENE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; PHARMACOGENETICS; PROCEDURES; TRENDS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHARMACOGENETICS; PRACTICE PATTERNS, PHYSICIANS'; PRECISION MEDICINE;

EID: 85020894341     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201018666170123153626     Document Type: Review

References (112)

1. World Health Organization. The top 10 causes of death. http://www.who.int/mediacentre/factsheets/fs310/en/(Accessed 27-Jul-2016).
2. World Economic Forum. The Global Economic Burden of Noncommunicable Diseases. http://www3.weforum.org/docs/WEF_Harvard_ HE_GlobalEconomicBurdenNonCommunicableDiseases_201 1.pdf (Accessed 27-Jul-2016).
3. Johnston, S.S.; Curkendall, S.; Makenbaeva, D.; Mozaffari, E.; Goetzel, R.; Burton, W.; Maclean, R. The direct and indirect cost burden of acute coronary syndrome. J. Occup. Environ. Med., 2011, 53(1), 2-7.
4. Armitage, J. The safety of statins in clinical practice. Lancet, 2007, 370(9601), 1781-1790.
5. Saiki, A.; Murano, T.; Watanabe, F.; Oyama, T.; Miyashita, Y.; Shirai, K. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J. Atheroscler. Thromb., 2005, 12(3), 163-168.
6. Ray, K.; Cannon, C. The potential relevance of the multiple lipidindependent (pleiotropic) effects of statins in the management of acute coronary syndromes. J. Am. Coll. Cardiol., 2005, 46(8), 1425-1433.
7. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; Davis, B.R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med., 1996, 335(14), 1001-1009.
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease in a broad range of initial cholesterol levels. N. Engl. J. Med., 1998, 339(19), 1349-1357.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 2002, 360(9326), 7-22.
10. Collins, R.; Armitage, J.; Parish, S.; Sleigh, P., Peto, R.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet, 2003, 361(9374), 2005-2016.
11. Colhoun, H.M.; Betteridge, D.J.; Durrington, P.N.; Hitman, G.A.; Neil, H.A.; Livingstone, S.J.; Thomason, M.J.; Mackness, M.I.; Charlton-Menys, V.; Fuller, J.H; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet, 2004, 364(9435), 685-696.
12. McClure, D.; Valuck, R.; Glanz, M.; Hokanson, J. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol. Drug Saf., 2007, 16, 132-143.
13. Keech, A.; Simes, R.J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M.R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesäniemi, Y.A.; Sullivan, D.; Hunt, D.; Colman, P.; d’Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366(9500), 1849-1861.
14. U S Food and Drug Administration Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/u cm071627.pdf (Accessed 27-Jul-2016).
15. EMA. ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002880.pdf (Accessed 27-Jul-2016).
16. Roden, D.M. Cardiovascular pharmacogenomics: current status and future directions. J. Hum. Genet., 2016, 61(1), 79-85.
17. Shahabi, P., Dube, M.P. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. Int. J. Cardiol., 2015, 184, 772-795.
18. Shahabi, P., Siest, G.; Meyer, U.A.; Visvikis-Siest, S. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol. Ther., 2014, 144(2), 134-161.
19. Beitelshees, A.L.; Voora, D.; Lewis, J.P. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers. Med., 2015, 8, 43-61.
20. Stankov, K.M., Stanimirov, B.G.; Mikov, M.M. Pharmacogenomic determinants of response to cardiovascular drugs. Medicinski pregled., 2015, 68(7-8), 259-265.
21. Rost, S.; Fregin, A.; Ivaskevicius, V.; Conzelmann, E.; Hörtnagel, K.; Pelz, H.J.; Lappegard, K.; Seifried, E.; Scharrer, I.; Tuddenham, E.G.; Müller, C.R.; Strom, T.M.; Oldenburg, J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 2004, 427(6974), 537-541.
22. Batt, A.M.; Magdalou, J.; Vincent-Viry, M.; Ouzzine, M.; Fournel-Gigleux, S.; Galteau, M.M.; Siest, G. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDPglucuronosyltransferases. Clin. Chim. Acta., 1994, 226(2), 171-190.
23. De Morais, S.; Wilkinson, G.; Blaisdell, J.; Nakamura, K.; Meyer, U.; Goldstein, J. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 1994, 269, 15419-15422.
24. De Morais, S.; Wilkinson, G.; Blaisdell, J.; Meyer, U.; Nakamura, K.; Goldstein, J. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in japonese. Mol. Pharmacol., 1994, 46, 594-598.
25. Scott, S.A.; Sangkuhl, K.; Gardner, E.E.; Stein, C.M.; Hulot, J.S.; Johnson, J.A.; Roden, D.M.; Klein, T.E.; Shuldiner, A.R. Clinical pharmacogenetics implementation consortium. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther., 2011, 90, 328-332.
26. Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Hockett, R.D.; Brandt, J.T.; Walker, J.R.; Antman, E.M.; Macias, W.; Braunwald, E.; Sabatine, M.S. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 2009, 360, 354-362.
27. Mega, J.L.; Simon, T.; Collet, J.P.; Anderson, J.L.; Antman, E.M.; Bliden, K.; Cannon, C.P.; Danchin, N.; Giusti, B.; Gurbel, P.; Horne, B.D.; Hulot, J.S.; Kastrati, A.; Montalescot, G.; Neumann, F.J.; Shen, L.; Sibbing, D.; Steg, P.G.; Trenk, D.; Wiviott, S.D.; Sabatine, M.S. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA, 2010, 304(1821-1830).
28. Holmes, M.; Perel, P.; Shah, T.; Hingorani, A.; Casas, J. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA, 2011, 306, 2704-2714.
29. Umemura, K.; Furuta, T.; Kondo, K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subject. J. Thromb. Haemost., 2008, 6, 1439-1441.
30. US Food and Drug Administration. FDA drug safety communication:reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm203888.htm (Accessed 27-Jul-2016).
31. Levine, G.N.; Bates, E.R.; Blankenship, J.C.; Bailey, S.R.; Bittl, J.A.; Cercek, B.; Chambers, C.E.; Ellis, S.G.; Guyton, R.A.; Hollenberg, S.M.; Khot, U.N.; Lange, R.A.; Mauri, L.; Mehran, R.; Moussa, I.D.; Mukherjee, D.; Nallamothu, B.K.; Ting, H.H; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol., 2011, 58, e44-e122.
32. Holmes, D.R. Jr.; Dehmer, G.J.; Kaul, S.; Leifer, D.; O’Gara, P.T.; Stein, C.M. ACCF/AHA clopidogrell clinical alert: approaches to the FDA “boxed warning”: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol., 2010, 56(321-341).
33. Wang, B.; Canestraro, W.J.; Choudhry, N.K. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. JAMA Intern. Med., 2014, 174(1938-1944).
34. US National Library of Medicine. Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI) (NCT01742117). https://clinicaltrials. gov/ct2/show/NCT01742117 (Accessed 27-Jul-2016).
35. Bergmeijer, T.O.; Janssen, P.W.A.; Asselbergs, F.W.; Schipper, J.C.; Van ‘T Hof, A.W.; Dewilde, W.J.M.; Postma, M.J.; De Boer, A.; Deneer, V.H.M.; Ten Berg, J.M. A tailored antiplatelet strategy in STEMI patients based on CYP2C19 genotyping is feasible in daily practice-POPular Genetics study. Eur. Heart J., 2014, 35, 191-192.
36. Malhotra, N.; Abunassar, J.; Wells, G.A.; McPherson, R.; Fu, A.; Hibbert, B.; Labinaz, M.; Le May, M.; Dick, A.; Glover, C.; Froeschl, M.; Marquis, J.F.; Tran, L.; Bernick, J.; Chong, A.Y.; So, D.Y; CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators. A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. Int. J. Cardiol., 2015, 197, 318-325.
37. Ito, S.; Woodland, C.; Harper, P.A.; Koren, G. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). Life Sci., 1993, 53(399-403).
38. Ito, S.; Woodland, C.; Harper, P.A.; Koren, G. P-glycoproteinmediated renal tubular secretion of digoxin: Toxicological significance of the urine-blood barrier model. Life Sci., 1993, 53, 25-31.
39. Koren, G.; Woodland, C.; Ito, S. Toxic digoxin-drug interactions:The major role of renal P-glycoprotein. Vet. Human Toxicol., 1998, 40, 45-46.
40. Administration UFaD. Drug development and drug interactions:table of substrates, inhibitors and inducers. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm (Accessed 27-Jul-2016).
41. Neuvonen, A.; Palo, J.; Sajantila, A. Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users. Int. J. Legal Med., 2011, 125(2), 265-269.
42. Chasman, D.; Posada, D.; Subrahmanyan, L.; Cooks, N.; Stanton, V.; Ridker, P. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA, 2004, 291(23), 2821-2827.
43. Donnelly, L.A.; Doney, A.S.; Dannfald, J.; Whitley, A.L.; Lang, C.C.; Morris, A.D.; Donnan, P.T.; Palmer, C.N. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipidlowering response to statin treatment in diabetes: A GoDARTS study. Pharmacogenet. Genomics, 2008, 18, 1021-1026.
44. Ordovas, J.M.; Lopez-Miranda, J.; Perez-Jimenez, F.; Rodriguez, C.; Park, J.S.; Cole, T.; Schaefer, E.J. Effect of apolipoprotein E and A-IV phenotypes on the low-density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis, 1995, 113, 157-166.
45. Fiegenbaum, M.; da Silveira, F.R.; Van der Sand, C.R.; Van der Sand, L.C.; Ferreira, M.E.; Pires, R.C.; Hutz, M.H. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfers protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin. Chim. Acta, 2005, 362, 182-188.
46. Peña, R.; Lahoz, C.; Mostaza, J.M.; Jiménez, J.; Subirats, E.; Pintó, X.; Taboada, M.; López-Pastor, A; Rap Study Group. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med., 2002, 251, 518-525.
47. Sanllehy, C.; Casals, E.; Rodriguez-Villar, C.; Zambón, D.; Ojuel, J.; Ballesta, A.M.; Ros, E. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism, 1998, 47, 560-565.
48. Donnelly, L.A.; Palmer, C.N.; Whitley, A.L.; Lang, C.C.; Doney, A.S.; Morris, A.D.; Donnan, P.T. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes. Pharmacogenet. Genomics, 2008, 18, 279-287.
49. Lagos, J.; Zambrado, T.; Rosales, A.; Salazar, L. APOE polymorphisms contributes to reduced atorvastatin response in Chilean Amerindian Subjects. Int. J. Mol. Sci., 2015, 16, 7890-7899.
50. Hu, M.; Lui, SS.; Mak, VW.; Chu, TT.; Lee, VW.; Poon, EW.; Tsui, TK.; Ko, GT.; Baum, L.; Tam, LS.; Li, EK.; Tomlinson, B. Pharmacogenetics of rosuvastatin in Chinese. Pharmacogenet. Genomics, 2010, 20, 634-637.
51. Merrill, R.; Ahrens, J.; Kaiser, M.; Federhart, K.; Poon, V.; Clagett-Dame, M. All-trans retinoic acid-responsive genes identified in the human SH-SY5Y neuroblastoma cell line and their regulated expression in the nervous system of early embryos. Biol. Chem., 2004, 385(7), 605-614.
52. Barber, M.J.; Mangravite, L.M.; Hyde, C.L.; Chasman, D.I.; Smith, J.D.; McCarty, C.A.; Li, X.; Wilke, R.A.; Rieder, M.J.; Williams, P.T.; Ridker, P.M.; Chatterjee, A.; Rotter, J.I.; Nickerson, D.A.; Stephens, M.; Krauss, R.M. Genome-wide association of lipidlowering response to statins in combined study populations. PloSOne, 2010, 5(e9763).
53. Drogari, E.; Ragia, G.; Mollaki, V.; Elens, L.; Van Schaik, R.H.; Manolopoulos, V.G. POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics, 2014, 15(16), 1963-1972.
54. Shim, H.; Chasman, D.I.; Smith, J.D.; Mora, S.; Ridker, P.M.; Nickerson, D.A.; Krauss, R.M.; Stephens M. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PloS One, 2015, 10(4), e0120758.
55. Li Josephine, H.; Suchindran, S.; Shah Svati, H.; Krauss, W.; Ginsburg, G.; Voora, D. SLCO1B1 genetic variants, long-term lowdensity lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics, 2015, 16(5), 449-458.
56. Soutar, A.K.; Naoumova, R.P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med., 2007, 4(4), 214-225.
57. Nordestgaard, B.G.; Chapman, M.J.; Humphries, S.E.; Ginsberg, H.N.; Masana, L.; Descamps, O.S.; Wiklund, O.; Hegele, R.A.; Raal, F.J.; Defesche, J.C.; Wiegman, A.; Santos, R.D.; Watts, G.F.; Parhofer, K.G.; Hovingh, G.K.; Kovanen, P.T.; Boileau, C.; Averna, M.; Borén, J.; Bruckert, E.; Catapano, A.L.; Kuivenhoven, J.A.; Pajukanta, P.; Ray, K.; Stalenhoef, A.F.; Stroes, E.; Taskinen, MR.; Tybjærg-Hansen, A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J., 2013, 34(45), 3478-90a.
58. Cuchel, M.; Bruckert, E.; Ginsberg, H.N.; Raal, F.J.; Santos, R.D.; Hegele, R.A.; Kuivenhoven, J.A.; Nordestgaard, B.G.; Descamps, O.S.; Steinhagen-Thiessen, E.; Tybjaerg-Hansen, A.; Watts, G.F.; Averna, M.; Boileau, C.; Borén, J.; Catapano, A.L.; Defesche, J.C.; Hovingh, G.K.; Humphries, S.E.; Kovanen, P.T.; Masana, L.; Pajukanta, P.; Parhofer, K.G.; Ray, K.K.; Stalenhoef, A.F.; Stroes, E.; Taskinen, M.R.; Wiegman, A.; Wiklund, O.; Chapman, M.J; Avrupa Ateroskleroz Derneği Ailevi Hiperkolesterolemi Uzlaşi Paneli. Homozygous familial hypercholesterolaemia: New insights and guidance for cilinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J., 2014, 35(32), 2146-2157.
59. Stein, E.; Honarpour, N.; Wasserman, S.; Xu, F.; Scott, R.; Raal, F. Effect of the PCSK9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation, 2013, 128(19), 2113-2120.
60. Dedoussis, G.V.; Skoumas, J.; Pitsavos, C.; Choumerianou, D.M.; Genschel, J.; Schmidt, H.; Stefanadis, C. FH clinical phenotype in Greek patients with LDL-R defective versus LDL-R negative mutations. Eur. J. Clin. Invest., 2004, 34(6), 402-409.
61. Bertolini, S.; Cassanelli, S.; Garuti, R.; Ghisellini, M.; Simone, M.L.; Rolleri, M.; Masturzo, P.; Calandra, S. Analysis of LDL receptor gene mutation in Italian patients with homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 1999, 19(2), 408-418.
62. Myant, N.B.; Gallagher, J.J.; Knight, B.L.; McCarthy, S.N.; Frostegård, J.; Nilsson, J.; Hamsten, A.; Talmud, P.; Humphries, S.E. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arterioscler. Thromb., 1991, 11(3), 691-703.
63. Abifadel, M.; Varret, M.; Rabès, JP.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003, 34, 154-156.
64. Abifadel, M.; Rabès, J.P.; Devillers, M.; Munnich, A.; Erlich, D.; Junien, C.; Varret, M.; Boileau, C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat., 2009, 30, 520-529.
65. Cohen, J.; Pertsemlidis, A.; Kotowski, I.; Graham, R.; Garcia, C.; Hobbs, H. Low LDL cholesterol in individuals of African descent resulting from nonsense mutations in PCSK9. Nat. Genet., 2005, 37(3), 161-165.
66. Folsom, A.R.; Peacock, J.M.; Boerwinkle, E. Variation in PCSK9, low LDL cholesterol and risk of peripheral arterial disease. Atherosclerosis, 2009, 202(1), 211-215.
67. Sehayek, E.; Butbul, E.; Avner, R.; Levkovitz, H.; Eisenberg, S. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors. Eur. J. Clin. Invest., 1994, 24(3), 173-178.
68. Istvan, E.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292(5519), 1160-1164.
69. Vogel, R. PCSK9 inhibition: The next statin? J. Am. Coll. Cardiol., 2012, 59(25), 2354-2355.
70. Sahebkar, A.; Simental-Mendia, L.; Guerrero-Romero, F.; Golledge, J.; Watts, G. Effect of statin therapy on plasma PCSK9 concentrations: A systematic review and meta-analysis of clinical trials. Diabetes Obes. Metab., 2015, 17(11), 1042-1055.
71. Lakoski, S.G.; Xu, F.; Vega, G.L.; Grundy, S.M.; Chandalia, M.; Lam, C.; Lowe, R.S.; Stepanavage, M.E.; Musliner, T.A.; Cohen, J.C.; Hobbs, H.H. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab., 2010, 95(2), 800-8009.
72. Tavori, H.; Rashid, S.; Fazio, S. On the function and homeostasis of PCSK9; reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis, 2014, 238(2), 264-270.
73. Nodari, S.; Rocca, P.; Saporetti, A.; Bettari, L.; Foresti, A.L.; Tanghetti, E.; Metra, M.; Dei Cas, L. The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. Heart Int., 2007, 3(1), 12.
74. Blom, D.J.; Hala, T.; Bolognese, M.; Lillestol, M.J.; Toth, P.D.; Burgess, L.; Ceska, R.; Roth, E.; Koren, M.J.; Ballantyne, C.M.; Monsalvo, M.L.; Tsirtsonis, K.; Kim, J.B.; Scott, R.; Wasserman, S.M.; Stein, E.A; DESCARTES Investigators. A 52-week placebocontrolled trial of evolocumab in hyperlipidemia. N. Engl. J. Med., 2014, 370(19), 1809-1819.
75. Robinson, J.G.; Nedergaard, B.S.; Rogers, W.J.; Fialkow, J.; Neutel, J.M.; Ramstad, D.; Somaratne, R.; Legg, J.C.; Nelson, P.; Scott, R.; Wasserman, S.M.; Weiss, R; LAPLACE-2 Investigators. Effects of evolocumab or ezetimibe added to moderate-or highintensity statin therapy on LDL-C lowering in patients with hypercholesterolemia:the LAPLACE-2 randomized clinical trial. JAMA, 2014, 311(18), 1870-1882.
76. Spinar, J.; Spinarova, L.; Vitovec, J. IMProved Reduction of Outcomes:Vytorin Efficacy International Trial (study IMPROVE-IT). Vnitr Lek, 2015, 60(12), 1095-1101.
77. Gouni-Berthold, I. Berthold, H.K. PCSK9 antibodies for the treatment of hypercholesterolemia. Nutrients, 2014, 6(12), 5517-5533.
78. Simon, J.A.; Lin, F.; Hulley, S.B.; Blanche, P.J.; Waters, D.; Shiboski, S.; Rotter, J.I.; Nickerson, D.A.; Yang, H.; Saad, M.; Krauss, R.M. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: The Cholesterol and Pharmacogenetics (CAP) Study. Am. J. Cardiol., 2006, 97(6), 843-50.
79. Cohen, J.C.; Pertsemlidis, A.; Fahmi, S.; Esmail, S.; Vega, G.L.; Grundy, S.M.; Hobbs, H.H. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. USA, 2006, 103(6), 1810-1815.
80. De Marinis, E.; Matini, C.; Trendalance, A.; Pallottini, V. Sex differences in hepatic regulation of cholesterol homeostasis. J. Endocrinol., 2008, 198, 635-643.
81. Ho, P.M.; Magid, D.J.; Shetterly, S.M.; Olson, K.L.; Maddox, T.M.; Peterson, P.N.; Masoudi, F.A.; Rumsfeld, J.S. Medication nonadherence is associated with broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J., 2008, 155(4), 772-779.
82. Jacobson, T. Toward “pain free” statin prescribing: Clinical algorithm for diagnosis and management of myalgia. Mayo Clin. Proc., 2008, 83(6), 687-700.
83. Bruckert, E.; Hayem, G.; Dejager, S.; Yau, C.; Begaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc. Drug Ther., 2005, 19(6), 403-414.
84. Buettner, C.; Davis, R.B.; Leveille, S.G.; Mittleman, M.A.; Mukamal, K. Prevalence of musculoskeletal pain and statin use. J. Gen. Intern. Med., 2008, 23(8), 1182-1186.
85. Hoffmann, K.; Kraus, C.; Dimbil, M.; Golomb, B. A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to statin drug class. PloSOne, 2012, 7, e42866.
86. Abd, T.; Jacobson, T. Statin-induced myopathy: A review and update. Expert Opin. Drug Sa., 2011, 10, 373-387.
87. Taha, D.; De Moor, C.; Barrett, D.; Gershkovich, P. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Trans. Res., 2014, 164, 85-109.
88. Mangravite, L.M.; Engelhardt, B.E.; Medina, M.W.; Smith, J.D.; Brown, C.D.; Chasman, D.I.; Mecham, B.H.; Howie, B.; Shim, H.; Naidoo, D.; Feng, Q.; Rieder, M.J.; Chen, Y.D.; Rotter, J.I.; Ridker, P.M.; Hopewell, J.C.; Parish, S.; Armitage, J.; Collins, R.; Wilke, R.A.; Nickerson, D.A.; Stephens, M.; Krauss, R.M. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature, 2013, 502, 377-380.
89. Needham, M.; Mastaglia, F.L. Statin myotoxicity: A review of genetic susceptibility factors. Neuromuscul. Disord., 2014, 24, 4-15.
90. SEARCH Collaborative Group.; Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy a genomewide study. N. Engl. J. Med., 2008, 359, 789-799.
91. Zeharia, A.; Shaag, A.; Houtkooper, R.H.; Hindi, T.; de Lonlay, P.; Erez, G.; Hubert, L.; Saada, A.; de Keyzer, Y.; Eshel, G.; Vaz, F.M.; Pines, O.; Elpeleg, O. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am. J. Hum. Genet., 2008, 83, 489-494.
92. Zhang, P.; Verity, M.A.; Reue, K. Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell. Metab., 2014, 20, 267-279.
93. Ramsey, L.B.; Johnson, S.G.; Caudle, K.E.; Haidar, C.E.; Voora, D.; Wilke, R.A.; Maxwell, W.D.; McLeod, H.L.; Krauss, R.M.; Roden, D.M.; Feng, Q.; Cooper-DeHoff, R.M.; Gong, L.; Klein, T.E.; Wadelius, M.; Niemi, M. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatininduced myopathy: 2014 update. Clin. Pharmacol. Ther., 2014, 96(4), 423-428.
94. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocrine Rev., 2004, 4, 581-611.
95. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350, 2335-2342.
96. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, C.M.; Figlin, R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 115-124.
97. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R.M; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 125-134.
98. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J; SHARP Investigators Study Group. Sorafenib imroves survival in advanced hepatocellular carcinoma: results of phase III randomized placebocontrolled trial (SHARP study). ASCO annual meeting proceedings part I. J. Clin. Oncol., 2007, 25, LBA1.
99. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355, 2542-2550.
100. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med., 2007, 357, 2666-2676.
101. Rini, B.I.; Rathmell, W.K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin. Cancer Res., 2007, 13, 741s-746s.
102. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed 27-Jul-2016).
103. Glusker, P.; Recht, L.; Lane, B. Reversible posterior leukoencephalopathy syndrome and Bevacizumab. N. Engl. J. Med., 2006, 354, 980-981.
104. Zhu, X.; Wu, S.; Dahut, W.L.; Parikh, C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systemic review and meta-analysis. Am. J. Kidney. Dis., 2007, 49, 186-193.
105. Debette, S.; Visvikis-Siest, S.; Chen, M.H.; Ndiaye, N.C.; Song, C.; Destefano, A.; Safa, R.; Azimi N.M.; Sawyer, D.; Marteau, J.B.; Xanthakis, V.; Siest, G.; Sullivan, L.; Pfister, M.; Smith, H.; Choi, S.H.; Lamont, J.; Lind, L.; Yang, Q.; Fitzgerald, P.; Ingelsson, E.; Vasan, R.S.; Seshadri, S. Identification of cis-and transacting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels. Circ. Res., 2011, 109(5), 554-563.
106. Stathopoulou, M.G.; Bonnefond, A.; Ndiaye, N.C.; Azimi-Nezhad, M.; El Shamieh, S.; Saleh, A.; Rancier, M.; Siest, G.; Lamont, J.; Fitzgerald, P.; Visvikis-Siest, S. A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. J. Lipid Res., 2013, 54(2), 535-541.
107. Azimi-Nezhad, M.; Stathopoulou, M.G.; Bonnefond, A.; Rancier, M.; Saleh, A.; Lamont, J.; Fitzgerald, P.; Ndiaye, N.C.; Visvikis-Siest, S. Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine, 2013, 61(2), 602-607.
108. IGNITE. The Implementing GeNomics in PracTicE (IGNITE) Network. https://www.genome.gov/27554264/(Accessed 27-Jul-2016).
109. ESPT. European Society of Pharmacogenomics and Personalised Therapy. www.esptnet.eu (Accessed 27-Jul-2016).
110. Shahabi, P.; Siest, G.; Visvikis-Siest, S. Clinical interest of pointof-care pharmacogenomic testing: Clopidogrel behind warfarin. Pharmacogenomics, 2012, 13(11), 1215-1218.
111. Koelsch, C.; Przewrocka, J.; Keeling, P. Towards a balanced value business model for personalized medicine: An outlook. Pharmacogenomics, 2013, 14(1), 89-102.
112. Molnár, J.M.; Magyarósi, S.; Németh, G. Significance of genetic tests in the era of personalized medicine. Magy Onkol., 2013, 57(1), 16-20.